Clinical Trials
18 trialsNCT07486817 2026-05-19
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Boehringer Ingelheim
Phase 2 Not yet recruiting
NCT07586202 2026-05-14
AmiNA
Janssen Research & Development, LLC
Phase 2 Not yet recruiting
NCT07524257 2026-05-04
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
ImmunityBio, Inc.
Phase 3 Not yet recruiting
NCT07554859 2026-04-28
GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Not yet recruiting
NCT07551778 2026-04-27
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
BOE Technology Group Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
NCT07383116 2026-02-03
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07256509 2025-12-05
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2 Not yet recruiting
NCT07154368 2025-09-19
JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.
Guangzhou JOYO Pharma Co., Ltd
Phase 3 Not yet recruiting
NCT07157956 2025-09-05
CVL006-T1002
Convalife (Shanghai) Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07109531 2025-08-07
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06970782 2025-05-21
KYLIN-3
Avistone Biotechnology Co., Ltd.
Phase 3 Not yet recruiting
NCT06594874 2024-09-19
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06514027 2024-07-23
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
BeBetter Med Inc
Phase 2 Not yet recruiting
NCT06380348 2024-04-23
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT06335355 2024-03-28
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 2/3 Not yet recruiting
NCT05990127 2023-08-14
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
Akeso
Phase 3 Not yet recruiting